Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02385669
Title A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Acronym Mel62; 6PAC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Age Groups: adult
Covered Countries USA

No variant requirements are available.